(Q44210599)

30 November 2017

Growth hormone receptor antagonist improves insulin resistance in acromegaly (English)

1 reference

30 November 2017

1 reference

1 reference

D Roderick Rose

1

1 reference

PubMed ID

12423627

30 November 2017

David R Clemmons

series ordinal

2

1 reference

30 November 2017

1 December 2002

1 reference

Growth Hormone & I G F Research

30 November 2017

1 reference

30 November 2017

12

1 reference

30 November 2017

6

1 reference

30 November 2017

418-424

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

30 November 2017

1 reference

7 January 2021

Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Effect of octreotide on glucose tolerance in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

1 reference

7 January 2021

Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Rational design of potent antagonists to the human growth hormone receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Non-insulin-mediated glucose uptake in several insulin-resistant states in the postabsortive period.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Loss of sensitivity to insulin at early events of the insulin signaling pathway in the liver of growth hormone-transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Peripheral glucose metabolism in acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS1096-6374%2802%2900083-7

7 January 2021

10.1016/S1096-6374(02)00083-7

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12423627